Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Exelixis, Inc. - Common Stock
(NQ:
EXEL
)
50.28
-0.20 (-0.40%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exelixis, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
BeiGene Stock Meets 80-Plus RS Rating Benchmark
↗
January 15, 2025
One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday.
Via
Investor's Business Daily
15 Analysts Have This To Say About Exelixis
↗
January 15, 2025
Via
Benzinga
BridgeBio Pharma Stock Earns 87 RS Rating
↗
January 14, 2025
BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87.
Via
Investor's Business Daily
NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals.
↗
January 14, 2025
EXELIXIS INC (NASDAQ:EXEL) is probably undervalued for the fundamentals it is displaying.
Via
Chartmill
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
↗
January 13, 2025
On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86.
Via
Investor's Business Daily
Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025
January 12, 2025
From
Exelixis, Inc.
Via
Business Wire
In the world of growth stocks, NASDAQ:EXEL shines as a value proposition.
↗
January 06, 2025
NASDAQ:EXEL is showing decent growth, but is still valued reasonably.
Via
Chartmill
(EXEL) - Analyzing Exelixis's Short Interest
↗
January 06, 2025
Via
Benzinga
Do Not Get Caught Holding Story Stocks- The Market Is Unforgiving
↗
January 12, 2025
The stock market is already oversold, just not washed out yet.
Via
Talk Markets
Topics
Stocks / Equities
Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
January 09, 2025
From
Exelixis, Inc.
Via
Business Wire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
↗
January 09, 2025
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Government
Peering Into Exelixis's Recent Short Interest
↗
December 18, 2024
Via
Benzinga
Expert Outlook: Exelixis Through The Eyes Of 19 Analysts
↗
December 17, 2024
Via
Benzinga
NASDAQ:EXEL is showing decent growth, but is still valued reasonably.
↗
December 16, 2024
EXELIXIS INC (NASDAQ:EXEL) is showing good growth, while it is not too expensive.
Via
Chartmill
SpringWorks Therapeutics Stock Gets A RS Rating Lift
↗
January 08, 2025
The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76.
Via
Investor's Business Daily
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
January 06, 2025
From
Exelixis, Inc.
Via
Business Wire
Arcellx Stock Earns 82 Relative Strength Rating
↗
December 27, 2024
Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.
Via
Investor's Business Daily
Investors should take notice of NASDAQ:EXEL—it offers a great deal for the fundamentals it presents.
↗
December 20, 2024
EXELIXIS INC (NASDAQ:EXEL) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via
Chartmill
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
↗
December 17, 2024
Via
Benzinga
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
↗
December 13, 2024
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends.
Via
Benzinga
2 Biotech Stocks to Buy Hand Over Fist in December
↗
December 07, 2024
Via
The Motley Fool
End Of Year Rally: 3 Stocks To Watch (InterDigital, Futu Holdings, Exelixis)
↗
December 01, 2024
As the calendar winds down, the stock market often heats up. This
Via
Talk Markets
Topics
Stocks / Equities
Ten Young Ones
↗
November 30, 2024
Here are a variety of lesser-known charts from my “Recents” watch list. Quite a few of them look like good bullish plays.
Via
Talk Markets
Topics
Stocks / Equities
NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals.
↗
November 29, 2024
EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.
Via
Chartmill
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
November 27, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
November 26, 2024
From
Exelixis, Inc.
Via
Business Wire
BioNTech Stock Got A IBD RS Rating Lift
↗
November 14, 2024
A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance.
Via
Investor's Business Daily
Vericel Stock Sees RS Rating Shoot Higher
↗
November 11, 2024
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79.
Via
Investor's Business Daily
NASDAQ:EXEL is an undervalued gem with solid fundamentals.
↗
November 08, 2024
For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals.
Via
Chartmill
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
November 07, 2024
From
Exelixis, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
